ResultsIQ

ResultsIQ › Latest results › Anlon Healthcare Limited

Anlon Healthcare Limited Q2 FY26 results deck summary

NSE: AHCL · BSE: 544497

Results deck of 19 Nov 2025, summarised by AI from the filing.

Q2 FY26 revenue ₹52.20 cr, PAT ₹9.32 cr; targeting 30% 3-year revenue CAGR.

Key takeaways

  1. Q2 revenue Revenue ₹52.20 cr (Q2FY25: ₹24.17 cr), PAT ₹9.32 cr (Q2FY25: ₹2.59 cr).
  2. Guidance Targeting 3-year revenue CAGR of 30% with gradual EBITDA margin improvement; 3–5 DMFs in FY27.
  3. Change EBITDA margin declined to 26.36% in Q2FY26 from 31.26% in Q2FY25.
  4. Driver China+1 strategy and new API launches (Artemether, Lumefantrine) drive growth.
  5. Risk High customer concentration: top 5 customers account for 77.62% to 100% of segment revenue.

Original filing on BSE

Anlon Healthcare Limited Q1 FY27 results

As filed: Revenue ₹31.0 cr (−6% year on year), EBITDA ₹7.5 cr (+24% year on year), PAT ₹4.8 cr (+20% year on year), EBITDA margin 24.1% (+590 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹55.4 cr, EBITDA ₹13.9 cr, PAT ₹9.8 cr, EBITDA margin 25.1%. Not scored. No result for the same quarter last year. Share price after the results: +14.3% in 27 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹35.6 cr, EBITDA ₹12.3 cr, PAT ₹5.2 cr, EBITDA margin 34.7%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹52.0 cr, EBITDA ₹13.0 cr, PAT ₹9.0 cr, EBITDA margin 25.0%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹33.0 cr, EBITDA ₹6.0 cr, PAT ₹4.0 cr, EBITDA margin 18.2%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anlon Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.